VF
NKTR icon

Virtu Financial’s Nektar Therapeutics NKTR Stock Holding History

Virtu Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,811
Closed -$584K – 2075
2025
Q4 		$584K Buy
+13,811
New +$773K 0.02% 540
2024
Q3 		– Sell
-5,004
Closed -$93K – 1709
2024
Q2 		$93K Buy
5,004
+3,887
+348% +$81.9K 0.01% 835
2024
Q1 		$16K Buy
+1,117
New +$11.7K ﹤0.01% 1198
2023
Q3 		– Sell
-912
Closed -$8K – 1684
2023
Q2 		$8K Buy
+912
New +$9.72K ﹤0.01% 1371
2023
Q1 		– Sell
-1,093
Closed -$37K – 1894
2022
Q4 		$37K Buy
+1,093
New +$52.9K ﹤0.01% 1138
2019
Q4 		$502K Buy
+1,551
New +$450K 0.05% 425
2019
Q3 		– Sell
-785
Closed -$419K – 1693
2019
Q2 		$419K Buy
+785
New +$394K 0.02% 614
2015
Q3 		– Sell
-1,527
Closed -$287K – 376
2015
Q2 		$287K Buy
+1,527
New +$263K 0.03% 267
2014
Q4 		– Sell
-1,056
Closed -$191K – 365
2014
Q3 		$191K Buy
+1,056
New +$202K 0.02% 275

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtu Financial's NKTR Position: Q1 2026 in Review

Virtu Financial sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 13,811 shares — an estimated $584K sold.

Virtu Financial first reported a position in NKTR in Q3 2014 and held it in 9 quarters. The position peaked at $584K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Virtu Financial reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 13,811 Nektar Therapeutics shares in Q1 2026, an estimated $584K.
  • Virtu Financial first reported a position in Nektar Therapeutics in Q3 2014 and held it in 9 quarters.
  • Virtu Financial's Nektar Therapeutics position peaked at $584K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.